High materiality7/10
Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
DNLI received an analyst target update from Stifel Nicolaus.
- Stifel reiterates Buy on DNLI; target $41; current price $23.76.
Key facts
- 01
Target: $41
- 02
Posted price: $23.76
- 03
Analyst firm: Stifel Nicolaus
- 04
Analyst: Paul Mattels
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.